The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted the public to the recall of Mivacron and Nimbex injections over safety concerns.
NAFDAC, in a statement on its X handle on Monday, said the products were manufactured by Aspen Pharmacare Asia Limited.
It said the recall followed safety concerns approved by the Hong Kong Department of Health.
According to the agency, one batch of Mivacron Injection 0.2 percent and five batches of Nimbex Injection 2mg/mL were affected.
“The recall was made as a precautionary measure due to potential quality issues identified by the manufacturer,” NAFDAC said.
Also Read
- 2027: Kwankwaso will run as Peter Obi’s deputy — Kwankwasiyya
- Peter Obi and the cross of a Nation, by Valentine Obienyem
- First Lady flags off 2026 planting season in Niger
- David Ogbueli and unseen architecture of global transformation, by Blaise Udunze
- 2027: Wike’s ally joins presidential race, picks PDP forms
It said investigations revealed deficiencies in the manufacturer’s manual visual inspection process.
NAFDAC added that “not all glass particles in the ampoules were likely detected,” prompting a voluntary market recall.
The injections, containing mivacurium and cisatracurium, are prescription medicines used as adjuncts to general anaesthesia.
NAFDAC advised healthcare professionals and consumers to report suspected substandard medicines to its nearest office or via its e-reporting platforms.
